FDA
-
-
-
-
-
-
-
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
-
-
-
-
-
-
-
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Biotech Q4 earnings preview: Goldman Sachs
-
-
-
-
-
-
-
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
-
-
-
-
-
-
-
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
-
-
-
-
-
-
-
Phathom Pharma (PHAT) Announces FDA Acceptance for Filing of VOQUEZNA Tablets NDA for Treatment of Heartburn Associated with Non-Erosive GERD
-
323,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

